中国卒中杂志
中國卒中雜誌
중국졸중잡지
CHINESE JOURNAL OF STROKE
2015年
2期
135-140
,共6页
赵一龙%郭安臣%王拥军%王群
趙一龍%郭安臣%王擁軍%王群
조일룡%곽안신%왕옹군%왕군
预适应%后处理%脑保护
預適應%後處理%腦保護
예괄응%후처리%뇌보호
Preconditioning%Post-conditioning%Cerebral protection
卒中是第3位常见的致死原因,给社会和经济带来沉重的负担。针对卒中的治疗多集中在急性期,而卒中恢复期的治疗尚无有效方法。有关药物治疗或无效或存在不良影响,相应的神经保护和大脑修复仍然是主要的尚未实现的医疗需求。近年来,大脑保护自身免受伤害性刺激以及修复内源性修复损伤越来越受关注。其中,对预适应的研究(也被称为诱导耐受性)已产生多种有希望治疗急性颅脑损伤的方法。一方面,预适应可以识别那些被诱导出的内源性保护或再生机制;另一方面,对于那些预期会发生缺血性事件的人群(如接受过脑部手术、短暂性脑缺血发作或蛛网膜下腔出血的患者),预适应可以作为一种治疗手段来诱导出耐受性。
卒中是第3位常見的緻死原因,給社會和經濟帶來沉重的負擔。針對卒中的治療多集中在急性期,而卒中恢複期的治療尚無有效方法。有關藥物治療或無效或存在不良影響,相應的神經保護和大腦脩複仍然是主要的尚未實現的醫療需求。近年來,大腦保護自身免受傷害性刺激以及脩複內源性脩複損傷越來越受關註。其中,對預適應的研究(也被稱為誘導耐受性)已產生多種有希望治療急性顱腦損傷的方法。一方麵,預適應可以識彆那些被誘導齣的內源性保護或再生機製;另一方麵,對于那些預期會髮生缺血性事件的人群(如接受過腦部手術、短暫性腦缺血髮作或蛛網膜下腔齣血的患者),預適應可以作為一種治療手段來誘導齣耐受性。
졸중시제3위상견적치사원인,급사회화경제대래침중적부담。침대졸중적치료다집중재급성기,이졸중회복기적치료상무유효방법。유관약물치료혹무효혹존재불량영향,상응적신경보호화대뇌수복잉연시주요적상미실현적의료수구。근년래,대뇌보호자신면수상해성자격이급수복내원성수복손상월래월수관주。기중,대예괄응적연구(야피칭위유도내수성)이산생다충유희망치료급성로뇌손상적방법。일방면,예괄응가이식별나사피유도출적내원성보호혹재생궤제;령일방면,대우나사예기회발생결혈성사건적인군(여접수과뇌부수술、단잠성뇌결혈발작혹주망막하강출혈적환자),예괄응가이작위일충치료수단래유도출내수성。
Stroke is the third most common cause of death after heart attack and cancer and has profound negative social and economic effects. Treatments for stroke are more concentrated in the acute period of stroke, and there is no effective method in the recovery period of stroke. Pharmacological treatments are either ineffective or confounded by adverse effects, and neuroprotection and brain repair in patients after acute brain damage are still major unfulfilled medical needs. Recently, endogenous mechanisms by which the brain protects itself against noxious stimuli and recovers from damage are being studied. Research on preconditioning, also known as induced tolerance, has resulted in various promising strategies for the treatment of patients with acute brain injury. On the one hand, preconditioning can identify endogenous protective or regenerative mechanisms that can be therapeutically induced. On the other hand, preconditioning could be used as a therapeutic technique by inducing tolerance in individuals in whom ischemic events are anticipated, such as high-risk surgical cohorts or patients with subarachnoid hemorrhage or transient ischemic attack.